NasdaqGM:ZNTLBiotechs
Zentalis Pharmaceuticals (ZNTL) Posts Zero Revenue Challenging Bullish Revenue Recovery Narratives
Zentalis Pharmaceuticals (ZNTL) has just posted its FY 2025 first half results with total revenue at US$0 million, basic EPS at a loss of US$1.05, and net income excluding extraordinary items at a loss of US$75.2 million. This puts the focus firmly on expense control and cash burn. Over the recent periods, the company has seen revenue move from US$40.6 million in the first half of 2024 to US$26.9 million in the second half of 2024, before dropping to zero in the latest half. Half year basic...